Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 2
2011 3
2012 3
2013 1
2016 1
2017 3
2018 1
2019 3
2020 1
2021 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Brehmer D, Beke L, Wu T, Millar HJ, Moy C, Sun W, Mannens G, Pande V, Boeckx A, van Heerde E, Nys T, Gustin EM, Verbist B, Zhou L, Fan Y, Bhargava V, Safabakhsh P, Vinken P, Verhulst T, Gilbert A, Rai S, Graubert TA, Pastore F, Fiore D, Gu J, Johnson A, Philippar U, Morschhäuser B, Walker D, De Lange D, Keersmaekers V, Viellevoye M, Diels G, Schepens W, Thuring JW, Meerpoel L, Packman K, Lorenzi MV, Laquerre S. Brehmer D, et al. Among authors: moy c. Mol Cancer Ther. 2021 Dec;20(12):2317-2328. doi: 10.1158/1535-7163.MCT-21-0367. Epub 2021 Sep 28. Mol Cancer Ther. 2021. PMID: 34583982 Free PMC article.
Five million years of Antarctic Circumpolar Current strength variability.
Lamy F, Winckler G, Arz HW, Farmer JR, Gottschalk J, Lembke-Jene L, Middleton JL, van der Does M, Tiedemann R, Alvarez Zarikian C, Basak C, Brombacher A, Dumm L, Esper OM, Herbert LC, Iwasaki S, Kreps G, Lawson VJ, Lo L, Malinverno E, Martinez-Garcia A, Michel E, Moretti S, Moy CM, Ravelo AC, Riesselman CR, Saavedra-Pellitero M, Sadatzki H, Seo I, Singh RK, Smith RA, Souza AL, Stoner JS, Toyos M, de Oliveira IMVP, Wan S, Wu S, Zhao X. Lamy F, et al. Among authors: moy cm. Nature. 2024 Mar;627(8005):789-796. doi: 10.1038/s41586-024-07143-3. Epub 2024 Mar 27. Nature. 2024. PMID: 38538940 Free PMC article.
Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.
Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, Perdomo C, Schaffer M, Liu G, Zhang S, Liu H, Vick J, Dhillon SS, Platero SJ, Dubinett SM, Stevenson C, Reid ME, Lenburg ME, Spira AE. Beane JE, et al. Among authors: moy c. Nat Commun. 2019 Apr 23;10(1):1856. doi: 10.1038/s41467-019-09834-2. Nat Commun. 2019. PMID: 31015447 Free PMC article.
Uranium isotope evidence for two episodes of deoxygenation during Oceanic Anoxic Event 2.
Clarkson MO, Stirling CH, Jenkyns HC, Dickson AJ, Porcelli D, Moy CM, Pogge von Strandmann PAE, Cooke IR, Lenton TM. Clarkson MO, et al. Among authors: moy cm. Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):2918-2923. doi: 10.1073/pnas.1715278115. Epub 2018 Mar 5. Proc Natl Acad Sci U S A. 2018. PMID: 29507196 Free PMC article.
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, Degenhardt Y. Jing J, et al. Among authors: moy c. Mol Cancer Ther. 2012 Mar;11(3):720-9. doi: 10.1158/1535-7163.MCT-11-0505. Epub 2011 Dec 14. Mol Cancer Ther. 2012. PMID: 22169769
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, Liu J, Dhaneshwar A, DePeaux K, Gowaski MR, Bailey D, Regan SN, Ivanova E, Ferrante C, English JM, Khosla A, Beck AH, Rytlewski JA, Sanders C, Laquerre S, Bittinger MA, Kirschmeier PT, Packman K, Janne PA, Moy C, Wong KK, Verona RI, Lorenzi MV. Palakurthi S, et al. Among authors: moy c. Cancer Immunol Res. 2019 Sep;7(9):1457-1471. doi: 10.1158/2326-6066.CIR-18-0595. Epub 2019 Jul 22. Cancer Immunol Res. 2019. PMID: 31331945
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).
Pillai RN, Ramalingam SS, Thayu M, Lorenzini P, Alvarez Arias DA, Moy C, Hutnick N, Knoblauch R, Feng H, Kane C, Horn L, Reck M, Ponce S; LUC2001 Investigators. Pillai RN, et al. Among authors: moy c. JTO Clin Res Rep. 2020 Oct 7;2(2):100104. doi: 10.1016/j.jtocrr.2020.100104. eCollection 2021 Feb. JTO Clin Res Rep. 2020. PMID: 34589982 Free PMC article.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Perera TPS, et al. Among authors: moy c. Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341788
20 results